Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer
- 6 September 2018
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 37 (2) , 315-322
Abstract
Summary Overexpression and cellular mis-localization of aurora kinase A (AURKA) in gastrointestinal cancers results in chromosomal instability, activation of multiple oncogenic pathways, and inhibition of pro-apoptotic signaling. Inhibition of AURKA causes mitotic delays, severe chromosome congression, and activation of p53/p73 leading to cell death. Our preclinical data showed cooperative activity with the AURKA inhibitor alisertib and platinum agents in cell lines and xenografts, and suggested an optimal treatment window. Therefore, this study was designed to determine the maximum-tolerated dose (MTD) of alisertib in combination with modified FOLFOX (mFOLFOX), as this is a standard platinum-based therapy for gastrointestinal cancers. Standard 3 + 3 dose escalation was used, where the starting dose of alisertib was 10 mg twice daily (Days 1–3), with leucovorin (400 mg/m2) and oxaliplatin (85 mg/m2) on Day 2 followed by continuous 46-h 5-FU (2400 mg/m2) infusion on Days 2–4 in 14-day cycles. Fourteen patients with advanced gastrointestinal cancers were enrolled and two doses explored; two patients were not evaluable for dose-limiting toxicity (DLT) and replaced. Two patients experienced DLTs at 20 mg of alisertib (Grade 3 fatigue (n = 2); Grade 3 nausea, vomiting, dehydration with hospitalization (n = 1)). MTD was 10 mg alisertib with 85 mg/m2 oxaliplatin and 2400 mg/m2 5-FU. Most frequent toxicities were nausea (57%), diarrhea, fatigue, neuropathy, and vomiting (43%), and anorexia and anemia (36%); most were Grade 1–2. One patient with colorectal cancer had a partial response of 12 evaluable patients, and four patients had stable disease. Alisertib in combination with mFOLFOX did not demonstrate unexpected side effects, but the regimen was only tolerable at the lowest dose investigated.Keywords
Funding Information
- National Cancer Institute (UM1 CA186689, P30 CA068485)
This publication has 45 references indexed in Scilit:
- Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid TumorsClinical Cancer Research, 2012
- The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma CellsMolecular Cancer Therapeutics, 2012
- The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinibJournal of Cellular and Molecular Medicine, 2011
- Aurora-A Kinase Is Essential for Bipolar Spindle Formation and Early DevelopmentMolecular and Cellular Biology, 2009
- The aurora kinase A regulates GSK-3β in gastric cancer cellsOncogene, 2008
- Aurora A Is Essential for Early Embryonic Development and Tumor SuppressionJournal of Biological Chemistry, 2008
- Aurora Kinase A Inhibition Leads to p73-Dependent Apoptosis in p53-Deficient Cancer CellsCancer Research, 2008
- MLN8054, a Small-Molecule Inhibitor of Aurora A, Causes Spindle Pole and Chromosome Congression Defects Leading to AneuploidyMolecular and Cellular Biology, 2007
- Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinaseProceedings of the National Academy of Sciences, 2007
- A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancersThe EMBO Journal, 1998